瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06938 瑞博生物-B

未开盘 08-18 16:08:03

51.850

+0.650

+1.27%

最高52.000	最低49.660	成交量19.46万
今开51.000	昨收51.200	日振幅4.57%
总市值88.15亿	流通市值88.15亿	总股本1.70亿
成交额987.30万	换手率0.11%	流通股本1.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":51.85,"timestamp":1787040483366,"preClose":51.2,"halted":0,"volume":194637,"delay":0,"changeRate":0.012695312499999972,"floatShares":170000000,"shares":170000000,"eps":-2.100221,"marketStatus":"未开盘","change":0.65,"latestTime":"08-18 16:08:03","open":51,"high":52,"low":49.66,"amount":9872989,"amplitude":0.045703,"askPrice":52,"askSize":2000,"bidPrice":51.85,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.805,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787103000000},"marketStatusCode":0,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":51.2,"openAndCloseTimeList":[[1787016600000,1787025600000],[1787029200000,1787040000000]],"volumeRatio":1.1133018289547376,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06938","defaultTab":"news","newsList":[{"id":"1164800741","title":"瑞博生物-B（06938）拟于8月27日审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1164800741","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164800741?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:51","pubTimestamp":1786956702,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司（06938）17日公告称，公司董事会已排定于2026年8月27日（星期四）召开会议，主要议程包括：一、审议并批准本集团截至2026年6月30日止六个月的中期业绩及其发布；二、研究及考虑是否派发2026年中期股息（如有）；三、处理其他相关事项。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196918869","title":"瑞博生物-B 7月股份变动月报：回购56.94万股并持作库存","url":"https://stock-news.laohu8.com/highlight/detail?id=1196918869","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196918869?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:16","pubTimestamp":1786007793,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年8月6日披露2026年7月股份变动月报表，报告期截止至2026年7月31日。报告期内，公司法定/注册股本保持人民币170,554,910元，已发行股份总数维持170,554,910股。此外，公司在上市前授出的2,113,987份股份期权仍未行使，每股行使价为人民币3.70元，因最早归属日期为2028年1月9日，报告期内无新增发行或行权情况。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656469589","title":"港股异动丨瑞博生物-B(06938.HK)盘中涨近4% 预期上半年实现收入同比增长至少约200%至320%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656469589","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656469589?lang=zh_cn&edition=full","pubTime":"2026-08-04 11:06","pubTimestamp":1785812793,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656933395","title":"险资投资策略大转向：战配、基石类升温 举牌节奏放缓","url":"https://stock-news.laohu8.com/highlight/detail?id=2656933395","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656933395?lang=zh_cn&edition=full","pubTime":"2026-08-01 02:10","pubTimestamp":1785521411,"startTime":"0","endTime":"0","summary":"中经记者樊红敏北京报道险资在资本市场的布局策略正在发生变化。一方面，险资参与上市公司IPO战略配售、基石投资的热度正在上升。7月27日，长鑫科技（688825.SH）正式登陆科创板，人保财险、中国人寿（601628.SH）、中邮人寿保、泰康人寿4家保险机构分别获配1154.73万股，对应认购金额均约1亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608013828783662.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608013828783662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["FWD","06082","601628","BK1521","01989","03986","VXUS","301085","001248","LU1720050803.USD","03968","03143","02513","LU0880133367.SGD","01288","06809","601112","LU1211504680.USD","LU0417516738.SGD","600009","06880","NBDS","03661","IE0008368742.USD","301680","LU0117841782.USD","LU0327786744.USD","REDS","00068","TECY","688825","BK0175","02476","FRHC","IPO","KCE","688005","LU0210526637.USD","000958","IPOS","KCAI","LU1880383440.USD","06938","001399","301666","688795","00100","LU1770034418.SGD","CWC","00501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105332142","title":"瑞博生物-B预计上半年收入达3.11亿至4.36亿元 同比增约200%至320%","url":"https://stock-news.laohu8.com/highlight/detail?id=1105332142","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105332142?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:21","pubTimestamp":1785320504,"startTime":"0","endTime":"0","summary":"2026年7月29日，瑞博生物-B发布正面财务信息预告，根据董事会对未經审计综合管理账目的初步评估，公司预计截至2026年6月30日止六个月的收入将在3.11亿元至4.36亿元之间，同比增幅约200%至320%。\\n\\n上述财务数据基于内部初步评估，尚未经过瑞博生物-B核数师或董事会审计委员会审核，最终数据将在公司预计于2026年8月底前发布的中期业绩公告中披露。\\n\\n公司提醒投资者在买卖其证券时保持审慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655660858","title":"瑞博生物-B(06938.HK)预期上半年实现收入约3.11亿-4.36亿元 同比增长约200%至320%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655660858","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655660858?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:19","pubTimestamp":1785320362,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152799579","title":"瑞博生物-B预计上半年营收增长，主要得益于与Madrigal Pharmaceuticals及勃林格殷格翰的合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1152799579","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152799579?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:19","pubTimestamp":1785320349,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司（证券简称：瑞博生物-B）预计，其上半年营收增长将主要受到与Madrigal Pharmaceuticals以及勃林格殷格翰（Boehringer Ingelheim）合作项目的强力驱动。这些合作伙伴关系有望为公司的收入增长注入强劲动力，成为其业绩亮点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142341313","title":"瑞博生物-B：核心产品vortosiran 2b期全球多区域临床试验获欧洲药管局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1142341313","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142341313?lang=zh_cn&edition=full","pubTime":"2026-07-28 20:11","pubTimestamp":1785240675,"startTime":"0","endTime":"0","summary":"2026年7月28日，苏州瑞博生物技术股份有限公司发布自愿公告称，其核心候选药物vortosiran针对心房颤动患者中风预防的2b期多区域临床试验已获欧洲药品管理局批准启动。瑞博生物-B强调，vortosiran的2b期临床试验获批系项目全球开发的重要里程碑，并将推动其进入下一阶段全球临床开发。不过，公司亦提示，vortosiran最终可能无法成功开发及商业化，提醒投资者审慎决策。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654017630","title":"瑞博生物-B(06938.HK)核心产品VORTOSIRAN针对SPAF的2B期临床试验获EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654017630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654017630?lang=zh_cn&edition=full","pubTime":"2026-07-28 20:01","pubTimestamp":1785240070,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198781631","title":"瑞博生物-B：7月24日回购7.84万股，耗资约422.37万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1198781631","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198781631?lang=zh_cn&edition=full","pubTime":"2026-07-24 20:41","pubTimestamp":1784896902,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年7月24日发布翌日披露报表，公告显示公司于当日回购H股78,400股，约占回购前已发行股本的0.0461%。回购价格介于每股港币52.6元至54.4元之间，总耗资约港币422.37万。公司公告指出，此次回购后，其已发行股本变动为169,985,510股，库藏股数增至569,400股，总股本维持170,554,910股。公司同时确认本次回购已获得董事会正式授权，并遵守香港联交所上市规则及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B：7月24日回购7.84万股，耗资约422.37万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653821850","title":"瑞博生物-B(06938)7月24日斥资约422.37万港元回购7.84万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653821850","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653821850?lang=zh_cn&edition=full","pubTime":"2026-07-24 20:40","pubTimestamp":1784896814,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年7月24日该公司斥资约422.37万港元回购7.84万股，回购价格为每股52.6至54.4港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653082188","title":"瑞博生物-B(06938.HK)7月24日斥资约422.37万港元回购7.84万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653082188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653082188?lang=zh_cn&edition=full","pubTime":"2026-07-24 20:40","pubTimestamp":1784896814,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164611703","title":"瑞博生物公布Vortosiran二期a阶段试验积极数据——全球首份关于siRNA介导的FXI抑制在冠状动脉疾病患者中多次给药后的临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1164611703","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164611703?lang=zh_cn&edition=full","pubTime":"2026-07-22 20:29","pubTimestamp":1784723391,"startTime":"0","endTime":"0","summary":"瑞博生物（RIBOLIFE-B）披露了其候选药物Vortosiran二期a阶段临床试验的积极结果。该数据标志着全球范围内，首次获得关于利用小干扰RNA（siRNA）技术抑制凝血因子XI（FXI），并在冠状动脉疾病患者中经过多次给药后所产生的临床效果信息。\n此次公布的试验数据展现了Vortosiran在目标患者群体中的潜力，为通过创新机制管理血栓风险提供了新的临床证据。该消息对关注前沿生物技术及心血管疾病治疗领域的投资者而言，无疑是一个重要的积极进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103771711","title":"瑞博生物-B 宣布Vortosiran IIa期试验未观察到严重不良事件或大出血事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1103771711","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103771711?lang=zh_cn&edition=full","pubTime":"2026-07-22 20:24","pubTimestamp":1784723053,"startTime":"0","endTime":"0","summary":"瑞博生物-B在Vortosiran的IIa期临床试验中，未观察到任何严重不良事件或大出血事件的发生。这一结果对该公司正在开发的候选药物而言，是一个积极的进展信号。试验数据表明，该药物在受试者中展现出可接受的安全性特征，为进一步的临床研究提供了支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653541227","title":"瑞博生物-B(06938)：FIC小核酸抗凝新药再添重磅新证，重塑治疗格局撬动百亿美元赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2653541227","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653541227?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:00","pubTimestamp":1784718000,"startTime":"0","endTime":"0","summary":"通过靶向FXI，vortosiran降低血栓形成风险，同时保留机体止血功能，有望解决心血管疾病领域的重大未满足医疗需求, 进一步验证vortosiran重塑全球抗凝治疗格局的FIC源头创新价值。例如今年5月，瑞博生物向EMA提交用于治疗CAD的小核酸药物RBD1119的II期临床试验申请。后续公司多款抗凝重磅药的关键数据读出及潜在获批，也将成为瑞博多产品矩阵协同发力，撬动百亿美元全球抗凝赛道，巩固自身FIC领先地位的决定性验证节点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470999.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174995112","title":"瑞博生物-B公布Vortosiran用于慢性冠状动脉疾病2a期试验积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1174995112","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174995112?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:35","pubTimestamp":1784709351,"startTime":"0","endTime":"0","summary":"2026年7月22日，瑞博生物-B发布自愿公告，披露其核心产品vortosiran在慢性冠状动脉疾病患者中的2a期试验取得积极结果。在完成维持剂量为400 mg的高剂量vortosiran给药后，受试者的凝血因子XI活性平均最大降幅达到92%，且抑制效果持续数月。瑞博生物-B提醒股东及潜在投资者，vortosiran最终可能无法成功开发及商业化，相关人士在买卖公司股份时应审慎行事。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653758039","title":"瑞博生物-B(06938)：核心产品VORTOSIRAN针对CAD的2A期积极研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2653758039","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653758039?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:33","pubTimestamp":1784709202,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B 发布公告，公司在上海举行的大国新药全球会议上公布了在欧洲进行的评估vortosiran 针对慢性冠状动脉疾病患者的2a期研究的积极结果。该项试验纳入具有心肌梗死病史且接受阿司匹林治疗的慢性CAD患者。在完成高剂量 vortosiran给药疗程、维持剂量为400 mg的患者中，FXI活性平均最大降幅达到 92%，且在给药后持续数月。通过靶向FXI，vortosiran 旨在降低血栓形成风险，同时保留机体止血功能，有望解决心血管疾病领域的重大未满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470871.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B(06938)：核心产品VORTOSIRAN针对CAD的2A期积极研究结果","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652400134","title":"瑞博生物-B(06938.HK)7月17日耗资383.2万港元回购7.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652400134","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652400134?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:27","pubTimestamp":1784287622,"startTime":"0","endTime":"0","summary":"格隆汇7月17日丨瑞博生物-B(06938.HK)公告，7月17日耗资383.2万港元回购7.9万股，每股回购价格45.88-50.55港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260717/32311035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141348912","title":"瑞博生物-B：7月17日回购7.9万股，耗资约383.24万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1141348912","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141348912?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:11","pubTimestamp":1784286680,"startTime":"0","endTime":"0","summary":"瑞博生物-B于2026年7月17日公告称，公司当天在香港联合交易所场内回购普通股7.9万股，占回购前公司已发行股份约0.0464%。本次回购价格范围为每股45.88港元至50.55港元，平均价格约48.5111港元，涉及总金额约383.24万港元。公告显示，本次回购后，公司于2026年7月17日的已发行股份数量由170,142,910股减少至170,063,910股，库存股份由412,000股增至491,000股，合计仍为170,554,910股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B：7月17日回购7.9万股，耗资约383.24万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162716391","title":"瑞博生物-B 2026年7月16日回购19.78万股，耗资约998.38万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162716391","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162716391?lang=zh_cn&edition=full","pubTime":"2026-07-16 19:16","pubTimestamp":1784200574,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司于2026年7月16日发布翌日披露报表，披露当日通过香港联交所场内回购普通股合计197,800股，占回购前已发行股本的0.1161%。本次回购的价格区间为每股49.98港元至50.55港元，共耗资9,983,758港元，折合约998.38万港元。截至目前，瑞博生物-B已在香港联交所或其他证券交易所总计回购412,000股，占授权通过当日已发行股本的0.2416%，相应剩余可回购股份数量为16,643,491股。公司确认，本次股份购回严格遵守了香港联交所证券上市规则及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"瑞博生物-B 2026年7月16日回购19.78万股，耗资约998.38万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ribolia.com","stockEarnings":[{"period":"1week","weight":-0.0272},{"period":"1month","weight":0.0603},{"period":"3month","weight":-0.0855},{"period":"6month","weight":-0.2707},{"period":"1year","weight":-0.1056},{"period":"ytd","weight":-0.1056}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":0.037},{"period":"3month","weight":-0.007},{"period":"6month","weight":-0.0462},{"period":"1year","weight":0.0117},{"period":"ytd","weight":-0.0062}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"苏州瑞博生物技术股份有限公司是一家主要从事小核酸药物研究和开发，尤其专注于小干扰核酸（siRNA）疗法的中国公司。该公司主要从事小核酸药物的创新，专注于心血管、代谢类、肾脏和肝病以及其他治疗领域。该公司的药物管线包括RBD4059、RBD5044、RBD7022、RBD7007、RBD2080、RBD1119、RBD1016等。该公司主要在中国国内市场开展业务。","exchange":"SEHK","name":"瑞博生物-B","nameEN":"RIBOLIFE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"瑞博生物-B,06938,瑞博生物-B股票,瑞博生物-B股票老虎,瑞博生物-B股票老虎国际,瑞博生物-B行情,瑞博生物-B股票行情,瑞博生物-B股价,瑞博生物-B股市,瑞博生物-B股票价格,瑞博生物-B股票交易,瑞博生物-B股票购买,瑞博生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"瑞博生物-B(06938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供瑞博生物-B(06938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}